Legend Biotech Corp. ADR (LEGN): Price and Financial Metrics

Legend Biotech Corp. ADR (LEGN): $50.65

0.99 (+1.99%)

POWR Rating

Component Grades













Add LEGN to Watchlist
Sign Up

Industry: Biotech



in industry

LEGN Stock Price Chart Interactive Chart >

Price chart for LEGN

LEGN Price/Volume Stats

Current price $50.65 52-week high $57.72
Prev. close $49.66 52-week low $30.75
Day low $48.87 Volume 289,800
Day high $50.80 Avg. volume 746,404
50-day MA $51.34 Dividend yield N/A
200-day MA $47.06 Market Cap 8.31B

Legend Biotech Corp. ADR (LEGN) Company Bio

Legend Biotech Corp. is a holding company which engages in the discovery and development of novel cell therapies for oncology and other indications. It carries out its operations through the North America, and China geographical segments. The company was founded in May 2015 and is headquartered in Somerset, NJ.

LEGN Latest News Stream

Event/Time News Detail
Loading, please wait...

LEGN Latest Social Stream

Loading social stream, please wait...

View Full LEGN Social Stream

Latest LEGN News From Around the Web

Below are the latest news stories about LEGEND BIOTECH CORP that investors may wish to consider to help them evaluate LEGN as an investment opportunity.

Genscript Bio Gets Booster From Subsidiary''s New Cancer Drug

Key Takeaways: After years of losses, Legend Biotech’s new cancer drug Cavykti offers it a chance to finally start contributing revenue to its parent, Genscript Biotech Some analysts believe Genscript may have become profitable last year, but also worry over its mounting R&D and sales expenses By Emily Chan The good news is coming thick and fast these days for Genscript Biotech Corp. (1548.HK). In early January, it disclosed that China’s National Medical Products Administration (NMPA) accepted its new drug application (NDA) for Cilta-cel , a chimeric antigen receptor T-cell (CAR-T) therapy being developed by its Legend Biotech (NASDAQ: LEGN ) subsidiary. Last Wednesday, it announced that sales of the new drug, marketed in the U.S. under the Carvykti name for treatment of multiple myelom...

Benzinga | February 2, 2023

Genscript Biotech (GNNSF) Gets Booster From Subsidiary’s New Cancer Drug

After years of losses, Legend Biotech’s new cancer drug Cavykti offers it a chance to finally start contributing revenue to its parent, Genscript Biotech.

Seeking Alpha | February 2, 2023

Investing in Legend Biotech Corporation (LEGN) might be an excellent idea, but the stock is currently overvalued/undervalued

The share price of Legend Biotech Corporation (NASDAQ:LEGN) rose to $50.50 per share on Tuesday from $50.13. While Legend Biotech Corporation has overperformed by 0.74%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, LEGN rose by 34.81%, with highs and lows ranging from $57.72 to $30.75, […]

US Post News | February 1, 2023

Legend Biotech: CARTITUDE-4 Study A Success (NASDAQ:LEGN)

Legend Biotech and partner JNJ announced positive topline results from the CARTITUDE-4 trial of Carvykti last week. See why LEGN stock is a Buy.

Seeking Alpha | January 31, 2023

Legend Biotech Announces Phase 3 CARTITUDE-4 Study of CARVYKTI® (ciltacabtagene autoleucel) Has Met Its Primary Endpoint in the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapi

Business Wire | January 27, 2023

Read More 'LEGN' Stories Here

LEGN Price Returns

1-mo 2.14%
3-mo -1.65%
6-mo 9.89%
1-year 19.09%
3-year N/A
5-year N/A
YTD 1.46%
2022 7.10%
2021 65.52%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.6134 seconds.